Predictive markers for treatment response in metastatic KRASmutant non-small cell lung cancer
Loading...
Date
2025
Authors
Ryan, Emily
Collins, Dearbhaile
Journal Title
Journal ISSN
Volume Title
Publisher
UCC Medical Research and Technology Society
Published Version
Abstract
Background: Non-small-cell lung carcinoma (NSCLC) represents 85% of all lung cancer cases, with Kirsten Rat Sarcoma Virus (KRAS) being the most commonly detected mutation. This study retrospectively reviews patient charts and databases to identify specific markers linked to favorable and poor responses to treatment in a tertiary care setting. Methods: Pre-treatment hematological, pathological, and biochemical data were gathered from 70 patients diagnosed with KRAS-mutant NSCLC at Cork University Hospital between January 1, 2017, and December 31, 2021. Patients were categorized by radiological response to treatment and progression-free survival (PFS). Statistical analysis was performed using SPSS v29, with parametric data expressed as mean (SD) and nonparametric data as median [IQR]. T-tests, Chi-squared tests, and Mann-Whitney U tests were employed, with a significance level of p <0.05. Results: The average age of patients was 66 years (10.2), with an age range of 36-86 years. The median PFS was 36 weeks [74
Description
Keywords
Metastatic KRASmutant non-small cell lung cancer
Citation
Ryan, E. and Collins, D. (2025) 'Predictive markers for treatment response in metastatic KRASmutant non-small cell lung cancer', UCC Student Medical Journal, 5, p.99. https://doi.org/10.33178/SMJ.2025.1.25